White Papers
Building a unified design-make-test-decide approach to drug discovery
Drug discovery has long followed a core loop: design a molecule, synthesize it, test its biological properties, and analyze the results to inform the next round of design.
Beyond algorithms: Building stronger AI foundations for drug discovery
Modern drug discovery produces more data than ever, from genomics and chemical screening to imaging and patient datasets
Leading the Way in Biotech Solutions Across JAPAC
Are you a U.S. biotech company struggling with patient recruitment, prolonged study timelines, rising costs, or unlocking the full value of your asset in key markets such as Japan or China
Quantifying the ROI of Integrated CDMO-CRO Models in Drug Development
As development costs climb and project timelines grow tighter, the traditional outsourcing model is showing its limitations.
Unlock Faster, More Confident Biosimilar Development
Developing biosimilars requires rigorous analytical characterization to ensure safety, efficacy, and regulatory approval.
Master Measurement Uncertainty in Laboratory Weighing
Every laboratory measurement carries some level of uncertainty—but in regulated environments, uncontrolled variation can compromise compliance, data integrity, and research outcomes.
Unlock Smarter Lifecycle Strategies for Injectable Therapeutics
As the injectable drug market continues to expand - driven by the rise of biologics, biosimilars, and patient-centric therapies-pharmaceutical companies face increasing pressure to differentiate their products, reduce costs, and optimize delivery systems.
Discover Why Douglas Softgels Are the Smarter Choice for Oral Drug Formulation
From improved stability and shelf-life to enhanced patient compliance, softgel technology is redefining oral medicines.
How to optimize your results and overcome specificity challenges in gene expression analysis
Real-time PCR for gene expression analysis is commonly used to quantify gene-specific RNA transcripts expressed by cells or viruses. However, gene expression analysis presents unique challenges, as experimental results often do not follow predictable patterns, and reliable positive controls are not always available.
New modalities, new tools Choosing a flexible digital platform for drug discovery
As pharmaceutical innovation rapidly evolves, the complexity of data generated from RNA therapeutics, gene therapies, antibody-drug conjugates (ADCs), and protein degraders necessitates a new approach to digital infrastructure.
